ScreenerHero

BIOA-B BioArctic AB (publ)

STO · SE · Healthcare · Biotechnology · bioarctic.se
302.20SEK+0.33%Mkt Cap: 2.57B $P/E: 256.10

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of biological drugs, such as antibodies that address high unmet medic…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
INSM
Insmed Incorporated
$22.98BUSD
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap2.57B USD
Enterprise Value2.41B USD
Revenue (TTM)95.89M USD
Gross Profit185.56M USD
Net Income (TTM)97.79M USD
Revenue/Share11.31 SEK
Last Price302.20 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees150
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)256.10
P/E (Forward)105.24
PEG—
EV/EBITDA—
EV/Revenue25.12
P/S27.02
P/B13.43
EPS (TTM)1.18
EPS (Forward)2.90
52W Range
257.0042% of range364.40
52W High364.40 SEK
52W Low257.00 SEK
Profitability
Gross Margin97.04%
Oper. Margin-5.76%
EBITDA Margin0.00%
Profit Margin51.14%
ROE51.97%
ROA39.70%
Growth
Revenue Growth-36.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF136.88M USD
CapEx (TTM)979.77K USD
FCF Margin19.18%
FCF Yield0.72%
Net Debt-181.68M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.02
Current Ratio3.99
Quick Ratio2.97
Book Value/Sh22.73 SEK
Cash/Share22.43 SEK
Dividends
Fwd Div Rate2.00 SEK
Trail. Div Rate2.00 SEK
Div. Yield0.66%
5Y Avg Yield—
Payout Ratio173.91%
Ex-Div DateMay 29, 2026
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)314.00 SEK
Upside (mean)+3.9%
Target Range270.00 SEK – 361.00 SEK
270.00+3.9% to mean361.00
# Analysts4
Ownership
Shares Out.74.34M
Float54.58M
Insiders42.34%
Institutions31.29%
Technical
SMA 50322.36 (-6.3%)
SMA 200319.06 (-5.3%)
Beta-0.69
S&P 52W Chg14.58%
Avg Vol (30d)157.32K
Avg Vol (10d)123.50K
Technical Indicators
RSI (14)38.1
MACD-5.4428
MACD Signal-3.4760
MACD Hist.-1.9668
BB Upper334.23 SEK
BB Middle316.26 SEK
BB Lower298.29 SEK
BB Width11.36%
ATR (14)9.279 SEK
Vol Ratio (20d)0.98x